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Veliparib in combination 
with radiotherapy for the treatment of MGMT 
unmethylated glioblastoma
Toni Rose Jue1, Kyoko Nozue1, Ashleigh J. Lester1, Swapna Joshi1, Lisette B. W. Schroder1, Shane P. Whittaker1, 
Sheri Nixdorf1, Robert W. Rapkins1, Mustafa Khasraw2 and Kerrie L. McDonald1*
Abstract 
Background: The O6-methylguanine methyltransferase (MGMT) gene is frequently unmethylated in patients with 
glioblastoma (GBM), rendering them non-responsive to the standard treatment regime of surgery followed by con-
current radiotherapy (RT) and temozolomide. Here, we investigate the efficacy of adding a PARP inhibitor, veliparib, to 
radiotherapy to treat MGMT unmethylated GBM.
Methods: The inhibition of PARP with veliparib (ABT-888), a potent and orally bioavailable inhibitor in combination 
with RT was tested on a panel of patient derived cell lines (PDCLs) and patient-derived xenografts (PDX) models gen-
erated from GBM patients with MGMT unmethylated tumors.
Results: The combination of veliparib and RT inhibited colony formation in the majority of PDCLs tested. The PDCL, 
RN1 showed significantly reduced levels of the homologous repair protein, Mre11 and a heightened response to PARP 
inhibition measured by increased apoptosis and decreased colony formation. The oral administration of veliparib 
(12.5 mg/kg, twice daily for 5 days in a 28-day treatment cycle) in combination with whole brain RT (4 Gy) induced 
apoptosis (Tunel staining) and decreased cell proliferation (Ki67 staining) in a PDX of MGMT unmethylated GBM. 
Significantly longer survival times of the PDX treated with the combination treatment were recorded compared to RT 
only or veliparib only.
Conclusions: Our results demonstrate preclinical efficacy of targeting PARP at multiple levels and provide a new 
approach for the treatment of MGMT unmethylated GBM.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Glioblastoma (GBM) is a uniformly lethal disease that 
has had few therapeutic advances over the past century. 
The standard treatment for GBM consists of radiother-
apy (RT) combined with temozolomide (TMZ) chemo-
therapy followed by at least six cycles of TMZ. The 
median survival is less than 15  months [1]. Survival is 
significantly worse for patients whose tumor is unmeth-
ylated at the O6-methylguanine-DNA methyltransferase 
(MGMT) promoter because they do not respond to DNA 
damaging therapy [2]. In a study by Hegi and colleagues, 
a survival benefit was seen in patients with MGMT meth-
ylated tumors: median survival 23.4  months compared 
to 12.6  months in those with non-methylated tumors 
treated with the concurrent RT and TMZ regimen [2]. 
Given the response to TMZ is limited, trials to find better 
therapies for GBM patients, particularly for those with an 
unmethylated MGMT promoter are imperative.
Inhibition of DNA repair by PARP inhibitors during 
RT and chemotherapy has been explored both pre-clin-
ically and clinically in numerous solid cancers including 
breast, ovarian, rectal, prostate, and lung cancer [3–6]. 
Sensitivity to PARP inhibitors is mediated by mutations 
in the BRCA1 and two genes, which result in the defec-
tive function of the homologous recombination (HR) 
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pathway [7–9]. PARP inhibitors act through synthetic 
lethality by targeting the base excision repair (BER) path-
way. Disruption of both HR and BER pathways lead to 
cell death. Clinically, the PARP inhibitor veliparib (ABT-
888; AbbVie) is being investigated in Phase three studies 
of several cancers including lung (NCT02264990), triple 
negative breast cancers (NCT02032277) and HER2 nega-
tive BRCA1/2 deficient breast cancers (NCT02163694).
Sensitivity to PARP inhibition has been observed in 
cancers that do not harbor BRCA1/2 deficiencies. Many 
other gene mutations, commonly found in cancer, result 
in recombination defects and hence the likely sensitiv-
ity to PARP inhibitors. Mutations in genes such as PTEN 
[10, 11], ATM [12, 13], PALB2 [14], CHEK2 [13, 15, 16], 
FANCA [15] and HDAC2 [16] have been implicated in 
patient response to PARP inhibitors. However, it is note-
worthy that >50 genes, many mutated in cancer, can con-
fer sensitivity to PARP inhibitors [4].
For the treatment of GBM, studies have focused on the 
use of PARP inhibitors as radio- or chemo-sensitizers 
[11, 17–20]. In a study using veliparib in combination 
with TMZ, sensitivity to TMZ was significantly improved 
in both MGMT promoter methylated and unmethylated 
cell lines [19]. However this chemo-sensitizing effect was 
not observed in  vivo when MGMT unmethylated lines 
were intracranially injected into immunocompromised 
mice, suggesting that only GBM that are MGMT methyl-
ated confer a benefit to combination treatment. A recent 
study evaluated the triple combination therapy consist-
ing of veliparib given concurrently with RT and TMZ in 
a genetically engineered mouse model whose induced 
GBM was sensitive to TMZ [21]. The study reported sta-
tistically significant improvement in overall survival of 
the mice treated with the triple combination; however 
this is not clinically relevant as the triple combination 
treatment incurs significant toxicity. A clinical trial eval-
uating veliparib in combination with adjuvant TMZ for 
newly diagnosed GBM patients with MGMT promoter 
methylation following standard RT is currently enrolling 
patients (NCT02152982).
The combination of PARP inhibitors with radiation 
therapy has also been trialed pre-clinically [22–24]. 
Venere and colleagues provided compelling evidence that 
GBM-initiating cells (GICs) express high levels of PARP1. 
These cells are typically resistant to RT [24]. Significant 
loss of viability in  vitro was observed when the PARP 
inhibitor, olaparib was combined with RT compared to 
either agent alone. Tumors were completely abolished 
with this combination when tested in vivo [24].
Treatment for MGMT unmethylated patients is a sig-
nificant unmet need and new treatments are urgently 
needed to (1) replace TMZ as a therapy and/or (2) to 
improve and sensitize tumors to the current standard 
of therapy. We have developed a large series of patient 
derived cell lines that are MGMT unmethylated. We pro-
posed to treat these cell lines with a combination of RT 
and veliparib to demonstrate that PARP inhibitors can 
be effective as radiosensitizers both in vitro and in vivo. 
In addition, we explored identification of biomarkers of 
response to the veliparib/RT combination so that this can 
be translated back to the clinic for patient stratification.
Methods
Drugs
Veliparib (ABT-888) was provided via a research agree-
ment with AbbVie. Temozolomide (TMZ) was purchased 
from Sigma Aldrich.
Patient derived cell lines (PDCLs)
The PDCLs, G13, G18, G28, G56, G54, G57 and G89, 
were generated from fresh GBM tumor tissue collected at 
time of surgery in accordance with appropriate approved 
institutional review board protocols. All patients signed a 
consent form prior to collection. Within 10 min of collec-
tion from surgery, tumor tissue was dissociated using the 
GentleMACS™ Dissociator (Miltenyi Biotec) in the pres-
ence of Accutase® solution (Sigma-Aldrich). Following 
addition of trypsin inhibitor (1:1 ratio; Sigma-Aldrich), 
cells were passed through a 100 µm Falcon™ cell strainer 
(Corning Inc.) to collect a suspension of single cells. Cen-
trifugation was performed at 300  rcf for 5  min at room 
temperature. Cell pellets were resuspended in RHB-A 
medium (Clontech Laboratories Inc.) supplemented 
with human epidermal growth factor (20 ng/mL; Sigma-
Aldrich) and human fibroblast growth factor—basic 
(20 ng/mL; Sigma-Aldrich), and were seeded into tissue 
culture flasks coated with a layer of BD Matrigel™ base-
ment membrane matrix (1:100 in PBS; BD Biosciences). 
Cells were maintained in a 37  °C, 5% CO2 incubator 
(Thermo Fisher Scientific). Initially, cultures were left 
undisturbed for 5  days prior to media replacement to 
allow for cell attachment. Following this period, cell lines 
underwent a media change twice weekly and were pas-
saged once a confluency of 80% was reached. The PDCLs, 
WK1 and RN1 were a generous gift from Dr Bryan Day, 
QIMR Berghofer. WK1 and RN1 were also maintained in 
RBH-A medium.
MGMT testing
All PDCLs were screened for MGMT promoter meth-
ylation using a pyrosequencing assay as described previ-
ously [25]. Briefly, DNA was extracted from the cell lines 
and converted with sodium bisulfite using the EZ Meth-
ylation-Gold kit (as per the manufacturers instructions; 
Zymo). The methylation-unbiased pyrosequencing assay 
was performed using the PyroMark MGMT kit (Qiagen) 
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on the PSQ24 MA system (Qiagen) and interrogated five 
individual CpG sites within exon one near the MGMT 
transcription start site for methylation [25] PyroMark 
CpG software (Qiagen) was used to quantify the levels of 
methylation. GBM cell lines were scored as methylation 
positive by pyrosequencing if all five CpG sites had meth-
ylation values of 9% or higher [25]. Chemically methyl-
ated and non-methylated genomic DNA was used as 
positive and negative controls, respectively (Millipore).
Colony formation assay
Colony formation assays for the PDCLs were performed as 
previously described [26]. PDCLs were plated in triplicate 
in 6-well plates and incubated overnight. The cells were 
treated with vehicle control (DMSO) or veliparib (10 μM) 
in supplemented RBH-A medium. Radiation was delivered 
using a self-contained X-ray system (X-RAD 320). Plates 
were incubated for 2  weeks undisturbed. Colonies were 
gently washed with PBS followed by staining and fixation 
with crystal violet solution (0.5% in H2O:methanol, 1:1) 
for 15  min. Stained colonies consisting of  >50 cells were 
counted and the number was recorded. Plating efficiency 
was calculated as the number of colonies counted divided 
by the number of cells seeded and normalized to the aver-
age plating efficiency of untreated samples. The average of 
these values was reported as “percentage of cells survived 
compared to the control.”
Cell proliferation assay
The optimum cell density of each PDCL was established 
using the MTS, CellTiter 96® Aqueous Assay (Promega®) 
and viability was measured 8  days post-treatment. 
PDCLs were treated with increasing concentrations of 
veliparib (1–10  μM); TMZ (100–300  μM) and/or radia-
tion (1–4  Gy) to determine the cytotoxic effects of the 
chemotherapeutic drugs, and the half-maximal inhibi-
tory concentration (IC50).
Flow cytometry
PDCLs were seeded in 6-well plates for 24-h. Cells were 
treated with veliparib (10 μM) 2 h prior to RT (4 Gy). The 
plates were incubated for a further 72-h. Fluoroscein iso-
thiocyante (FITC)-conjugated Annexin V and propidium 
iodide (PI) stains (Roche) were used to measure apop-
totic cell death. In brief, treated cells were harvested and 
the cell pellet was stained with Annexin-V-FITC and/or 
PI diluted in incubation buffer (1:50) following the manu-
facturer’s protocol. Apoptosis was measured using flow 
cytometry (BD FACScanto™ II).
Western blot
Protein was extracted from untreated PDCLs using 
cell lysis buffer (10 mM Tris–Cl pH 7.4, 100 mM NaCl, 
1 mM EDTA pH 8.0, 1 mM NaF, 20 mM Na4P2O7, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% 
Glycerol, Milli-Q water) and complete, mini, EDTA-
free protease inhibitor tablets (Sigma Aldrich). Western 
blots were probed with antibodies against Mre11 (Mouse 
monoclonal [12D7], 1:500) and Rad50 (Mouse monoclo-
nal [13B3/2C6], 1:500). To control for protein loading, 
membranes were probed with EIF4E (Rabbit monoclonal 
[C46H6], 1:1000).
In vivo experiments
Female athymic nude mice (Balb/c; 8–9  weeks of age) 
were intracranially injected with 2 × 105 RN1 PDCLs ste-
reotactically in the right caudate putamen using the coor-
dinates: 1 mm anterior, 1.5 mm lateral, and 3.0 mm below 
the bregma. To monitor tumor growth, animals were 
humanely euthanized at the following time-points: 40, 45, 
50 and 60 days. Mouse brains were fixed in formalin and 
embedded in paraffin. H&E stains of the brains revealed 
tumor growth by day 45, indicating the time of com-
mencement of treatment. Mice were randomly assigned 
to four groups; (1) untreated control (n = 5); (2) veliparib 
only (12.5 mg/kg, twice daily gavage for 5 days in a 28-day 
treatment cycle) (n = 5); (3) radiation treatment (total of 
4 Gy over 2 days) (n = 5) and (4) veliparib combined with 
radiation (n  =  7). Whole brain radiation was delivered 
using a self-contained X-ray system (X-RAD 320). During 
RT, mice were placed in a customized lead box to shield 
the body to allow radiation to be delivered directly to the 
entire brain. The total radiation dose administered was 
4 Gy at a clinically relevant 2 Gy/fraction schedule on two 
consecutive days. Two cycles of veliparib were adminis-
tered to the mice, before endpoint was reached.
Mice were euthanized when they exhibited symptoms 
indicative of significant compromise to neurologic func-
tion and/or a greater than 20% body weight loss. Ani-
mal survival was defined as the time taken from tumour 
injection until euthanasia and survival curves were estab-
lished using the Kaplan–Meier estimator.
Immunohistochemistry
At the time of euthanasia, all brains were resected, forma-
lin fixed and embedded in paraffin. Sections were cut at 
4 μm and mounted on ultrafrost slides. All sections were 
deparaffinized in xylene and rehydrated in PBS using an 
ethanol gradient and a heat-mediated antigen retrieval 
step was performed using the Target Retrieval Solution 
(Dako, S1700) at 95 °C for 20 min. Sections were stained 
with an antibody against the proliferative marker, Ki67 
(Monoclonal mouse anti-human Ki67 [MIB-1 clone] 
1:100 Dako). A biotinylated polyclonal goat anti-mouse 
immunoglobulin (1:300 Dako) was used as the secondary 
antibody.
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Sections were also stained using the in situ Cell Death 
Detection Kit, POD (Roche) to measure the degree of 
DNA strand breaks (TUNEL technology), a hallmark of 
apoptosis.
Both Ki67 and TUNEL positive tumour cells (nuclear 
staining) were counted in five random fields (20× magni-
fication) per section and presented as percentage positive 
staining.
Statistics
Statistical significance was calculated with GraphPad 
Prism Software utilizing a one- or two-way ANOVA with 
a Bonferroni’s post hoc test, Students t test or log-rank 
(Mantel-Cox) test, where appropriate (GraphPad Soft-
ware Inc., San Diego, CA, USA). Data are represented as 
the mean ± S.D.
Results
MGMT unmethylated PDCLs respond to veliparib 
in combination with radiation treatment (RT)
Pyrosequencing to determine MGMT promoter meth-
ylation was performed on 15 individual GBM PDCLs. 
Approximately nine PDCLs (RN1, WK1, G13, G18, G28, 
G56, G54, G57 and G89) were confirmed to be MGMT 
unmethylated. These cell lines were selected for further 
analysis.
Six MGMT unmethylated PDCLs (RN1, WK1, G13, 
G18, G28 and G56) were treated with different concen-
trations of veliparib for 72 h to determine the inhibitory 
concentration to kill 50% of cells (IC50) (Fig.  1a). High 
doses of veliparib were required to achieve IC50 for all 
PCDLs (18 up to 80 μM) indicating that veliparib would 
not be effective in GBM as a monotherapy. We combined 
veliparib (5 and 10 μM) with IC50 doses of TMZ (150 μM 
for G13, G18 and WK1; 300  μM for G28 and RN1) 
(Fig.  1b). In agreement with previous studies [19], sig-
nificant synergism between the two drugs was observed 
in all cell lines, except for WK1. Gupta and colleagues 
reported potent efficacy when veliparib was combined 
with TMZ in vitro, however these results did not trans-
late to an effect in vivo [19].
Our primary objective was to determine if MGMT 
unmethylated cells responded to a combination of RT 
and veliparib. The effect on cell viability was measured 
by the ability of cells to form colonies. Clonogenic assays 
were performed in triplicate for G18, WK1, G53, RN1, 
G54 and (Fig. 2a–f). Cells were treated with a low dose of 
veliparib (10 μM) and irradiated with 1, 2 or 4 Gy 2 h later 
and incubated for a further 10 days before the counting 
of colonies and presented as a percentage of the control. 
For most of the cell lines, the ability to form colonies was 
significantly impeded when treated with veliparib and 
radiotherapy (2  Gy) (Fig.  2a–d). RN1 (Fig.  2d) was the 
most sensitive cell line to the combined treatment of veli-
parib and RT (1–4 Gy), recording over 50% colony inhibi-
tion. In contrast, two PDCLs (G54 and G57) showed little 
response to any of the treatment arms (Fig. 2e, f ).
Combination of veliparib and RT induces apoptosis
The PDCLs RN1, G54, G57 and G89 were treated with RT 
(4 Gy) and veliparib (10 μM) for 3 days. Media and drug 
were replenished daily. Cells were harvested and stained 
with Annexin V and propidium iodide to measure apop-
totic cell death. Figure  2g summarizes the percentage of 
cells that are either (a) live; (b) in early apoptosis; (c) in late 
apoptosis or (d) necrotic. Treatment of RN1 with the com-
bination of veliparib and RT showed a significant increase 
in the percentage of cells undergoing early–late apoptosis 
compared to control, veliparib only and RT only. The per-
centage cells positive for apoptosis was 33.8% compared 
to 6.6, 13.0 and 14.0% for control, veliparib only and RT 
only, respectively (p < 0.001). There was a slight increase 
Fig. 1 Effect of veliparib on MGMT unmethylated patient derived cell 
lines. a Dose-response curves of PDCLs treated with veliparib com-
pared to untreated cells. b Combination of veliparib (0, 5 or 10 μM) 
with temozolomide (TMZ; 150 or 300 μM). Bar graphs represent per-
centage viability of cells after 8 days of treatment. Error bars represent 
the standard deviation of three individual experiments. Significance 
determined by student t-test where ***(p < 0.001)
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in percentage cells undergoing apoptosis for G57 when 
treated with the combination of veliparib and RT, however 
this did not reach significance. No significant changes in 
apoptosis were detected for the resistant cell lines, G54 
and G89 when treated with the combination.
Loss of the MRN complex confers sensitivity to veliparib 
and radiotherapy
We performed Western blot analysis to examine the 
protein expression of Mre11 and Rad50 in the four 
PDCLs, RN1, G54, G57 and G89. Mre11 and Rad50 
form a complex with the Nbs protein and play a key role 
in the sensing, processing and repair of double strand 
breaks. Significantly lower Mre11 protein expression 
was detected in RN1 (Fig. 2h, i) which was the most sen-
sitive cell line to the combination of veliparib and RT, 
implicating loss of the MRN complex as a possible mech-
anism for sensitivity.
Combining veliparib and RT leads to longer survival in an 
orthotopic model
We evaluated the combination treatment further by 
intracranially injecting balb/c nude mice with RN1 cells. 
We allowed the tumor to develop for 45 days (confirmed 
by histology) before commencing treatment. Consist-
ent with observed chemo-radiosensitization in  vitro, 
the combination of veliparib and RT resulted in signifi-
cant survival benefit in the RN1 mouse model compared 
to veliparib alone or RT alone (Fig. 3a). Median survival 
for mice treated with the combination was 83 days com-
pared to veliparib alone (64 days) and RT alone (73 days) 
(LogRank p value = 0.042).
Fig. 2 Combination of veliparib and radiotherapy. Patient derived cell lines were treated with veliparib (10 μM) for 2 h before irradiation with 0, 1, 
2 and 4 GY. Cells were seeded in wells and the ability to form clones was monitored over a 10-day period. a G18; b WK1; c G53; d RN1; e G54 and f 
G57. Bar graphs represent the percentage of clones counted with respect to the control. g Veliparib and radiotherapy induce apoptotic cell death in 
patient derived cell lines. RN1, G54, G57 and G89 cells were treated with veliparib (10 μM) for 2 h before irradiation with 2 GY. h Protein expression 
of Rad50 and Mre11 were assessed in untreated PDCLs, RN1, G54, G57 and G89. i Quantification of Rad50 and Mre11 protein expression for each 
PDCL. Error bars represent the standard deviation of three individual experiments. Significance determined by student t-test where ***(p < 0.001); 
**(p < 0.01); *(p < 0.05)
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Mouse brains were resected from euthanized animals, 
formalin fixed and paraffin embedded and sectioned 
for immunohistological staining with the proliferation 
marker, Ki67 and the apoptosis marker, Tunel (Fig. 3b–d). 
Examination of the H&E sections confirmed GBM had 
formed in all cases, hallmarked by increased mitotic bod-
ies, necrosis and microvascular proliferation (Fig.  3b). 
Interestingly we noted that the number of mitoses per 
low powered field was markedly reduced in the brains 
from mice treated with the combination of veliparib and 
RT. This observation was confirmed by the percentage 
of cells stained positive for Ki67 (Fig.  3b, c). On aver-
age, less than 5% of tumor cells stained positive for Ki67 
when treated with the combination compared to 12 and 
14% for RT alone and veliparib alone, respectively. To 
our surprise, nuclei positivity for Tunel in combination 
treated tumors was dramatic, with over 90% of nuclei 
staining positive for Tunel (Fig.  3b, d). Tunel positive 
nuclei were also observed in tumors treated with RT only 
(40%) with very few cells positive in the veliparib only or 
untreated control tissues.
Discussion
The inhibition of PARP has been shown to be efficacious 
when combined with TMZ, however, enhanced survival 
was only observed in MGMT methylated GBM [19]. These 
results formed the foundation for the clinical trial evaluat-
ing veliparib in combination for newly diagnosed MGMT 
methylated GBM patients (NCT02152982). However, 
patients diagnosed with MGMT unmethylated GBM have 
Fig. 3 Treatment of a MGMT unmethylated PDX mouse model with oral veliparib and radiotherapy. a Kaplan–Meier survival curves demonstrate 
a significant survival advantage when mice were treated with the combination of veliparib and radiotherapy. The treatment schedule consisted of 
concomitant veliparib (12.5 mg/kg, twice daily gavage for 5 days in a 28-day cycle) and radiotherapy (total of 4 Gy given over 2 days). b Histology 
of resected tumors post-treatment. The top panel displays the H&E, middle panel are stained for Ki67 while the bottom panel are stained for Tunel. 
(i, v and ix are tumors resected from control mice; ii, vi, x are tumors resected from veliparib monotherapy treatment; iii, vii, xi are tumors resected 
from radiotherapy only treatment and iv, viii, xii are tumors resected from the combination of veliparib and radiotherapy. Representative images of 
three mice per group are shown). c Quantitative analysis of the Ki67 staining in all treatment groups; d Quantitative analysis of the Tunel staining in 
all treatment groups. Error bars represent the standard deviation of three individual experiments. Significance determined by student t-test where 
***(p < 0.001); **(p < 0.01); *(p < 0.05)
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a worse prognosis are more effective therapies are urgently 
needed. We, herein, proposed the question: could veliparib 
sensitize MGMT unmethylated tumors to RT?
We utilized our GBM patient-derived cell lines, which 
were all tested for MGMT and found to be unmethylated 
to address this question. As with previous studies, we 
found veliparib as a monotherapy did not have an appre-
ciable effect on cell viability in vitro or on tumor growth 
in  vivo. However, when given in a concomitant fashion 
with RT, apoptotic cell death was induced, the ability to 
form colonies was reduced and the overall survival of our 
orthotopic model significantly increased.
Concomitant veliparib and RT has been tested previ-
ously in a subcutaneous model, however this is the first 
study demonstrating a significant effect of the combina-
tion treatment in an orthotopic model. We demonstrated 
an extension of 10 days in survival times for mice treated 
with the combination when compared to RT as a mono-
therapy. Tumors were significantly reduced in size and 
demonstrated high levels of apoptosis (detected by Tunel 
staining) and a lower proliferation index (measured by 
Ki67 staining). This positive signal has provided the foun-
dations for a clinical trial in Australia: A Randomised 
Phase II study of veliparib and RT with adjuvant TMZ 
and veliparib versus standard RT and TMZ followed 
by TMZ in patients with newly diagnosed GBM with 
unmethylated O(6)-methylguanine-DNA methyltrans-
ferase (The VERTU study; ANZCTR: U1111-1167-6365). 
Over 20 patients have been randomized and the combi-
nation treatment has been well tolerated. The study aims 
to enroll 120 patients.
An important observation was made in the in  vitro 
studies of veliparib and RT. Not all of the MGMT 
unmethylated cell lines responded favorably to treat-
ment. The PDCLs, G54 and G89 did not show significant 
impediment of their ability to form colonies and the rate 
of apoptosis was not significantly different to the control 
cells. We tested the protein expression levels of Mre11 
and Rad50. Together with Nsb1, they form the MRN 
complex that is involved in the detection and repair of 
DNA double-strand breaks (DSBs). The most sensitive 
PDCL, RN1 demonstrated significantly reduced expres-
sion of Mre11 protein. Reduced Mre11 expression has 
been implicated in mediating sensitivity to PARP inhi-
bition in endometrial and colorectal cancers [27, 28]. 
Colorectal cancer cells harboring biallelic Mre11 muta-
tions were more sensitive to the PARP inhibitor, LT-626 
and stable overexpression or knock-down of Mre11 in 
cell lines correlated with sensitivity [28]. We have not 
screened our PDCLs for mutations in the Mre11 gene 
however, the clinical samples collected as part of the 
VERTU trial will be tested for both mutations and pro-
tein expression.
Conclusion
We have shown that concomitant veliparib and RT is an 
effective treatment for MGMT unmethylated GBM. One 
caveat however, will be to screen patients on trial for bio-
markers predictive of sensitivity as we have shown that 
not all patients will respond to the treatment.
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